Švicarska - francuski - Swissmedic (Swiss Agency for Therapeutic Products)

sun store health care ag - dextromethorphanum - sirop contre la toux - dextromethorphanum 25 mg ut dextromethorphani hydrobromidum, magnesii aluminii silicas, ethanolum 96 per centum 50 mg, acidum citricum monohydricum, natrii citras dihydricus, cellulosum microcristallinum et carmellosum natricum, sorbitolum liquidum non cristallisabile 5.5 g, aqua purificata, aromatica, propylenglycolum 8.6 mg, natrii cyclamas 2-ethyl-3-hydroxy-4-pyronum, e 150a, propylis parahydroxybenzoas 3 mg, e 218 10 mg ad suspensionem pro 10 ml corresp. natrium 31.7 mg. - la toux - synthetika

Švicarska - francuski - Swissmedic (Swiss Agency for Therapeutic Products)

sun store health care ag - dextromethorphanum - hustentabletten - dextromethorphanum 25 mg pour dextromethorphani hydrobromidum, e 200, excipiens pro compresso de la brume. - la toux - synthetika

Švicarska - francuski - Swissmedic (Swiss Agency for Therapeutic Products)

sun store health care ag - carbocisteinum - sirop - carbocisteinum 750 mg, ethanolum 96 per centum 59 mg, natrii hydroxidum, sorbitolum liquidum non cristallisabile 8.528 g, acidum citricum monohydricum, aqua purificata, ammonii glycyrrhizas, aromatica (banane, kirsche), e 150(a), propylis parahydroxybenzoas natricus 4 mg, e 219 37 mg ad solutionem pro 15 ml corresp. natrium 100.8 mg. - mukolytikum - synthetika

Švicarska - francuski - Swissmedic (Swiss Agency for Therapeutic Products)

sun store health care ag - xylometazolini hydrochloridum, dexpanthenolum - spray nasal - xylometazolini hydrochloridum 1 mg/ml corresp. xylometazolini hydrochloridum 100 µg pour dosi, dexpanthenolum 50 mg/ml corresp. dexpanthenolum 5 mg pro dosi, excipiens ad solution de 1 ml, les doses pour que le navire 100. - rhume - synthetika

Europska Unija - francuski - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - sitagliptin fumarate - diabète sucré, type 2 - les médicaments utilisés dans le diabète - for adult patients with type 2 diabetes mellitus, sitagliptin sun is indicated to improve glycaemic control:as monotherapy:- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. as dual oral therapy in combination with:- metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control. - a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance. - a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. a thiazolidinedione) when use of a pparγ agonist is appropriate and when diet and exercise plus the pparγ agonist alone do not provide adequate glycaemic control. as triple oral therapy in combination with:- a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. - a pparγ agonist and metformin when use of a pparγ agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. sitagliptin sun is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.

Belgija - francuski - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

krka d.d. novo mesto d.d. - malate de sunitinib 16,71 mg - eq. sunitinib 12,5 mg - gélule - sunitinib

Belgija - francuski - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

krka d.d. novo mesto d.d. - malate de sunitinib 33,41 mg - eq. sunitinib 25 mg - gélule - sunitinib

Belgija - francuski - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

krka d.d. novo mesto d.d. - malate de sunitinib 66,83 mg - eq. sunitinib 50 mg - gélule - sunitinib

Europska Unija - francuski - EMA (European Medicines Agency)

sun pharmaceutical industries (europe) b.v. - ertapénème sodique - infections bactériennes - ertapenem - treatmentertapenem sun is indicated in paediatric patients (3 months to 17 years of age) and in adults for the treatment of the following infections when caused by bacteria known or very likely to be susceptible to ertapenem and when parenteral therapy is required (see sections 4. 4 et 5. 1):- intra-abdominal infections- community acquired pneumonia- acute gynaecological infections- diabetic foot infections of the skin and soft tissue (see section 4. 4)preventionertapenem sun is indicated in adults for the prophylaxis of surgical site infection following elective colorectal surgery (see section 4. la considération devrait être donnée à des recommandations officielles concernant l'utilisation appropriée des antibactériens.

Kanada - francuski - Health Canada

sandoz canada incorporated - sunitinib - capsule - 12.5mg - sunitinib 12.5mg